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Abstract 
The delivery of Peptide Nucleic Acids (PNAs) to cells is a very challenging task. We here report that 
a liposomal formulation composed of egg PC/cholesterol/DSPE-PEG2000 can be loaded, according 
to different encapsulation techniques, with PNA or fluorescent PNA oligomers. PNA loaded 
liposomes efficiently and quickly promote the uptake of a PNA targeting the microRNA miR-210 in 
human erythroleukemic K562 cells. By using this innovative delivery system for PNA, down-
regulation of miR-210 is achieved at a low PNA concentration. 
  
 
  
Introduction 
Oligonucleotide analogues are currently employed for therapeutic and scientific issues as 
modulator of gene expression both in vitro and in vivo; the discovery of non-coding RNAs has 
widened the field of application of these molecules1. Analogues with high stability to degradation 
in vivo are optimal drug candidates, but their delivery into cells still represents a challenging task. 
Peptide Nucleic Acids (PNAs) are oligonucleotide analogues composed by an uncharged backbone 
and characterized by a marked ability to hybridize complementary DNA and RNA strands with high 
affinity and specificity2, 3. PNAs have been proposed as anti-sense molecules targeting mRNAs, as 
decoy molecules targeting transcription factors, as antigene for the targeting of DNA double 
helices and  more interestingly, as agents able to inhibit the function of miRNAs 4-6. This last 
application of PNAs is of great interest, since the so called “miRNA therapeutics” is a fast growing 
field in applied biomedicine7, in consideration of the central role of microRNA in the control of 
gene expression in both physiological and pathological conditions8. PNAs are very resistant to 
degradation, but their poor cellular uptake severely hampers their use. The methodologies 
explored so far to convey PNA into cells are all based on the modification of the PNA oligomers 
and often require laborious synthetic procedures9-11. PNA monomers having the backbone 
functionalized with amino acid side chains have been largely explored. Modified PNAs bearing on 
the backbone positively charged arginine or lysine side chains effectively cross cell membranes 12, 
13; negatively charged moieties such as sulfate and phosphonate installed on the PNA backbone 
allowed delivery of PNA by standard cationic liposomes14, 15. 
An alternative strategy to improve the cellular uptake of PNAs is based on their conjugation to 
carrier peptides. Positively charged peptides such as Tat, NLS and polyarginine, are usually 
conjugated at one end of the PNA; the resulting molecules show an increased ability to be 
internalized by target cells16. In a recent application, the delivery of a PNA to a tumor has been 
achieved by a peptide specific for acidic microenvironments, which are typical of tumors: the 
pHLIP peptide, which forms a transmembrane alpha helix at low pH, has been conjugated to an 
antimiR-155 PNA and has been demonstrated to inhibit miR-155 in a mouse lymphoma model17. 
Silica nanoparticles have been linked to PNA by disulfide bond to achieve delivery and release of 
antisense PNAs in HeLa cells18; biodegradable PLGA formulations have been successfully employed 
for the delivery in vivo of PNA-polylysine conjugates in hematopoietic cells19. The main drawback 
of the cited strategies derives from the need of synthesizing special building blocks to be used in 
the solid phase synthesis or to conjugate on solid phase or in solution the carriers, ending up in 
very large molecules. 
Usually nucleic acids are delivered into cells by cationic liposomes, such as N-[1-dioleyloxy)propyl]-
N,N,N-trimethylammonium (DOTMA) and dioleoylphophatidylethanolamine (DOPE) in a 1:1 
phospholipid mixture,  and  2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-
propanammonium trifluoroacetate (DOTAP). The cationic head of these liposomes allows the 
complexation of the negatively charged phosphate groups of DNA/RNA, the linker region affects 
the stability and biodegradability of the liposome while the hydrophobic region anchors the 
cationic lipid into the bilayer20. Unfortunately, cationic liposomes are not suitable for the delivery 
of PNAs, unless they are hybridized or conjugated to DNA 21-23. 
In this paper we show that Peptide Nucleic Acid oligomers can be incorporated into egg 
phosphatidylcholine/cholesterol/1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carbonyl-
methoxy(polyethylene glycol)2000] (egg PC/Chol/DSPE-PEG2000) liposomes and efficiently 
delivered to cells.  
This finding has important implications for in vivo use of these oligonucleotide analogues: PNA 
oligomers made exclusively of commercially available PNA monomers are delivered to cells, 
without further modifications, and can exert their function at low concentrations.  
 
Results  
 
Liposome preparation and structural characterization 
PNA-antimiR210 and FLUO-PNA-antimiR210 derivatives were encapsulated in mixed egg 
PC/Chol/DSPE-PEG2000 liposomes at 47/47/6 molar ratio. Loading of the PNAs molecules was 
assessed by exploring three different methods: thin film method/sonication (a), freeze/thawing (b) 
and SNALPs (c). Empty liposomes were also prepared according to these procedures.  
 
Figure 1 reports a schematic representation of the freeze/thawing encapsulation method. 
 
 
 
Figure 1: Preparation of PNA loaded liposomes according to the freeze/thawing encapsulation 
method. In the first step the mixture of lipids was dried under vacuum to form a lipid film, then 
the PNA solution is added to the vial and liposomes encapsulating PNA are obtained.  
 
The liposomes containing PNA-a210 and its fluorescent derivative, namely LIPO-PNA-a210 and 
LIPO-FLUO-PNA-a210, were characterized by DLS measurements from the structural point of view 
and by UV-Vis spectroscopy for definition of encapsulation properties. Structural data and 
encapsulation efficiency are reported in Table 1; DLS profiles of PNA loaded liposomes are 
reported in Figure 2.  
 
From the inspection of Table 1, only slight differences can be observed between the mean 
diameter values obtained with the three loading procedures (78 ÷ 114 nm). In all cases, samples 
encapsulating FLUO-PNA-antimiR210 showed a lower size (~ 10% of decrease) with respect to 
those encapsulating PNA-antimiR210. On the other hand, it is worth noting a significant decrease 
of the polydispersity index for both preparations obtained with the loading procedure (b). 
Moreover, any substantial difference has been revealed in the encapsulation efficiency achieved 
with the three procedures (see Table 1). An increase in the encapsulation efficiency can be 
obtained by the post-insertion method (Table S1).  
 
 
 
 
 
Figure 2: Dynamic light-scattering plots of liposomes encapsulating PNA-antimiR210 (LIPO PNA-
a210) and FLUO-PNA-antimiR210 (LIPO FLUO-PNA-a210) prepared according to the 
freeze/thawing method.   
 
 
Table 1: Structural parameters (hydrodynamic diameters, polydispersity indexes, PDI, and 
diffusion coefficients, D) from dynamic light scattering measurements and encapsulation efficiency 
(%) of liposomes prepared by methods a, b and c. 
 
Method Compound diameter (nm) ± S.D. PDI D [m2s-1]х10-12 EE(%) 
(a) 
PNA-a210 85±46 0.148 5.8±3.1 1.69 
FLUO- PNA-a-210 78±32 0.132 6.2±2.5 0.67 
(b) 
PNA-a210 100±35 0.087 4.9±1.7 1.75 
FLUO- PNA-a-210 95±28 0.054 5.1±1.5 0.73 
(c) 
PNA-a210 114±58 0.160 4.3±2.2 1.85 
FLUO- PNA-a-210 102±49 0.148 4.8±2.3 0.82 
 
As expected empty liposomes, containing 47 mol% of PC zwitterionic phospholipid and 6 mol% of 
DSPE-PEG2000 anionic phospholipid, have a Z potential value of -31.13 mV. After loading with 
PNA-a210 or with its fluorescent derivative FLUO-PNA-a210, values were -26.4 and -23.6 mV, 
respectively. PNA loaded liposomes can be lyophilized and stored at -20°C; neither leakage of 
PNAs nor changes in the liposome dimensions and PDI are observed upon re-suspension in water 
and sonication of lyophilized liposomes (Table S2). 
Stability of liposomes loaded with PNAs was also assessed in fetal bovine serum. After incubation 
with serum, liposomal suspension dimensions were monitored by DLS measurements for 72 hours. 
As indicated in Figure 3, any variation in the liposomal diameter occurs, thus indicating its high 
stability under these experimental conditions. 
 
 
Figure 3: Stability of LIPO-PNA-a210 in 90% fetal bovine serum. 
 
Liposomes labelled with rhodamine encapsulating the FLUO-PNA-antimiR210 (Rho-LIPO-FLUO-
PNA-a210, were also prepared and employed to detect the cellular uptake of PNA-a210 in K562 
cells by confocal microscopy. 
 
 
Uptake of PNAs by K562 cells  
 
Uptake studies were carried out employing K562 cells as experimental model system, using the 
following fluorescently labelled molecules: FLUO-PNA-a210, FLUO-PNA-a210-R8 (a PNA targeting 
miR-210 and conjugated to a polyarginine R8 sequence) and the LIPO-FLUO-PNA-a210 
formulation. Figure 4A (panels A and B) shows a first set of experiments in which K562 cells were 
cultured for 4 hours in the presence of 2M and 4 M FLUO-PNA-a210, FLUO-PNA-a210-R8 and 
LIPO-FLUO-PNA-a210 and were analyzed by FACS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Uptake of PNAs. A,B. Representative FACS analysis of K562 cells cultured for 4 hours in 
the presence of the indicated concentrations of FLUO-PNA-a210 (A), LIPO-FLUO-PNA-a210 (A) and 
FLUO-PNA-a210-R8 (B). C. Kinetics of uptake of 2 M FLUO-PNA-a210 (open triangles), 4 M 
FLUO-PNA-a210 (black triangles), 2 M LIPO-FLUO-PNA-a210 (open circles), and 4 M LIPO-FLUO-
PNA-a210 (black circles). D. Representative microscopic analysis showing intracellular localization 
of LIPO-FLUO-PNA-a210 (arrowed) in K562 cells. E,F. Microscopic analysis of: a) K562 cells, phase-
contrast analysis; b) K 562 cells stained with DAPI and treated for 24 hours with 1 M FLUO-PNA-
a210 (E) and LIPO-FLUO-PNA-a210 (F), (c) merge. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Uptake of PNA: confocal microscopy analyses. A. Representative confocal microscopic 
analysis of K562 cells cultured in the presence of FLUO-PNA-a210 (24 hours, 1 µM). B. 
Representative live images of K562 cells after 24h incubation with 1 µM Rho-LIPO-FLUO-PNA-
a210. Fluorescence profile was run across the x-y axes of the cell body and orthogonal view of 
merged image was obtained with confocal Z-stack. 
 
As expected, low uptake levels were found when FLUO-PNA-a210 was employed. This is perfectly 
in agreement with results previously published by our research group demonstrating that the 
PNA-a210 is internalized by target cells only if it is linked to a octarginine R8 peptide 24, 25. The 
summary of the time course of the uptake is shown in Figure 4C, which indicates that uptake of 
LIPO-PNA-a210 is fast and a plateau level is reached between 4 and 24 hours culture period. No 
appreciable uptake of FLUO-PNA-a210 by K562 cells was detectable even after 48 hours of culture. 
The representative microscopic analyses shown in Figure 4 (panels D-F) demonstrate that no 
evidence of intracellular uptake of FLUO-PNA-a210 is detectable (Figure 4E). By contrast, 
liposomes carrying the FLUO-PNA-a210 bind to the cellular membrane and, when internalized, are 
located mostly in the intracellular matrix (Figure 4, D and F). When staining of nuclei is performed 
(Figure 4F,b), we can conclude that no liposome-mediated delivery of FLUO-PNA-a210 is 
detectable at nuclear level, and the localization is mostly cytoplasmic. To conclusively demonstrate 
intracellular localization of LIPO-PNA-a210, confocal microscopic analysis was performed on living 
cells (Figure 5). Figure 5A shows that, in agreement with the FACS data shown on Figure 4A and 
the microscopic analysis shown in Figure 4E, no uptake of FLUO-PNA-a210 is detectable, since 
almost all of the fluorescence was found outside the cells. On the contrary, when rhodamine-
labelled liposomes carrying FLUO-PNA-a210 (Rho-LIPO-FLUO-PNA) were employed, most of the 
fluorescence was found within the cells, formally demonstrating liposome-mediated uptake of the 
PNA-a210 (Figure 5B).  In any case, these results were considered a promising background to 
investigate possible effects on miR-210 in LIPO-FLUO-PNA-a210 treated cells. Taken together, the 
data shown in Figures 4 and 5 strongly suggest that the liposomes facilitate cellular binding and 
uptake of FLUO-PNA-a210 molecules. 
 
Effects of LIPO-PNA-a210 on miR-210 in K562 cells 
 
In order to determine whether the exposure to LIPO-PNA-a210 leads to alteration of miR-210 in 
K562 cells, RNA isolated from treated cells was used for RT-qPCR reactions amplifying miR-210. 
We first determined the effects of the different treatments (48 hours incubation) on cell growth  
(Figure S1). 
 
 
 
 
 
 
 
Figure 6: Real time detection of miR-210 in K562 cells treated for 48 hours with PNA-a210 (A), 
LIPO-PNA-a210 (A), LIPO-PNA-a210-scr (A), PNA-a210-R8 (B) and antagomiR-210 reference control 
(B), used at the indicated concentrations. RNA was extracted and RT-qPCR identifying miR-210 was 
performed and compared to control untreated K562 cells. Results represent the average  S.D. of 
three independent experiments (*, p<0.05, significant; **, p<0.01, highly significant). 
 
 
Interestingly, the LIPO and the LIPO-PNA-a210 preparations caused only minor effects on the rate 
of cell growth, demonstrating lack of cytotoxic activity (Figure S1). When K562 cells were cultured 
in the presence of LIPO-PNA-a210 a very reproducible effect was obtained, as shown in Figure 6. 
The results demonstrate that the miR-210 specific hybridization signal was reduced when RNA was 
isolated from K562 cells cultured for 48 h in the presence of LIPO-PNA-a210 (Figure 6A).  
On the contrary, the PNA-a210, lacking the R8 peptide, was not effective, in agreement with 
elsewhere published results 26. Notably, no effects were found using the liposomes carrying a 
scrambled PNA (LIPO-PNA-a210-scr) (Figure 6A). As positive controls we employed the elsewhere 
validated PNA-a210-R8 and a commercially-available antagomiR-210 26, 27. The results obtained are 
shown in Figure 6B, and support the concept that the LIPO-PNA-a210 formulation approaches the 
activity of these already validated anti-miR-210 reagents. As far as specificity, we verified this issue 
by analyzing the levels of an additional microRNA, miR-221, in K562 cells treated with LIPO-PNA-
a210. The data conclusively demonstrated that the effects of LIPO-PNA-a210 were selective, as no 
major effects were obtained in treated cells on miR-221  (Figure S2). 
 
Discussion 
Liposomes have been successfully applied for the in vivo delivery of drugs and contrast agents28-33; 
several liposomal formulations have been approved by FDA and are employed in clinic for drug 
delivery in the cure of various diseases ranging from cancer (Doxil), to fungal infections 
(Ambisome) to age related macular degeneration (Visudyne)34.  
  The composition of the liposome, which determines its structural properties (size, external 
charge, polydispersity index, transition temperature, drug loading and release), its stability in the 
biological fluids and also the ability to circulate for long times, is chosen based on the molecule 
that has to be encapsulated. The most used phospholipids for preparation of liposomal drugs 
including peptides are HSPC (L-α-phosphatidylcholine, hydrogenated soy), DOPC (1,2-dioleoyl-sn-
glycero-3-phosphocholine), DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), PC, DSPE (1,2-
distearoyl-sn-glycero-3-phosphoethanolamine); all of them contain two saturated or unsaturated 
alkyl chains composed of eighteen carbon atoms. In most preparations cholesterol is added in 
order to favour membrane stabilization or a fluidizing effect on lipid bilayers35. The introduction of 
flexible PEG chains exposed on the liposome surface has been reported to hide the liposome 
surface and prevent liposome interaction with MPS macrophages, thus providing stealth 
liposomes characterized by an increased circulation time20. Instead, liposome/DNA complexes 
(Lipoplexes) are usually prepared using cationic lipids such as DOPE, DOTMA, DOTAP. The positive 
surface charge favours the electrostatic interaction of the nucleic acid with the liposome.  
PNA oligomers, presenting a peptide backbone and nucleotidic bases, can be considered hybrid 
molecules with intermediate features between a nucleic acid and a peptide; due to the lack of 
charges on the backbone, PNAs do not efficiently interact with cationic liposomes. For this reason 
we have investigated PNA encapsulation in a liposomal composition, reported to efficiently deliver 
peptides into cells29, based on the zwitterionic egg PC, cholesterol and DSPE-PEG2000, according 
to different experimental procedures, and the ability of the loaded vehicle to carry PNA oligomers 
inside cells. The PNA sequences were designed to be complementary to miR-210, a non-coding 
RNA whose expression can be induced by mithramycin, which is associated to erythroid 
differentiation of leukemic K562 cells, regulation of raptor and -globin genes36. 
    
We explored three different encapsulation techniques: thin film method/sonication and 
freeze/thawing method which are usually employed for the entrapment of peptide derivatives in 
the liposomal inner compartment, and SNALPs method, which is preferred for the DNA or siRNA 
encapsulation37. The freeze/thawing method was found to yield lower PDI of the liposomes, as 
compared to the other methods, and was therefore employed to encapsulate PNA oligomers for in 
vitro studies. A further advantage of this method is that it permits to avoid the presence of traces 
of ethanol required during the SNALPs preparation, which are hardly removed and may be toxic to 
cells.  
Encapsulation efficiency (EE%) and encapsulation ratio (ER%) for PNA-antimiR210 in liposomes 
using the freeze/thawing method are 0.175 and 55 %, respectively. The values obtained using the 
other two methods above reported are very similar and all of them are in good agreement with 
data reported in literature for the encapsulation of siRNAs38. On the contrary, a noticeable 
difference can be underlined for FLUO-PNA-antimiR210 with respect to PNA-antimir210 with a 
decrease of EE% from 1.70÷1.85 to 0.70÷0.80. This decrease in the loading can be ascribed to the 
lower solubility of the fluorescently labeled derivative as compared to the unlabeled peptide 
nucleic acid. The encapsulation efficiency can be further improved (≈ 30%)   by PEG post-insertion. 
This result is probably due to the reduction of the membrane permeability (pore formation) in the 
lipid bilayer as a consequence of introduction of the highly flexible PEG head group. Moreover, the 
PEG insertion favors a better packing of the water-hydrocarbon interface, which also could reduce 
the membrane permeability. Once prepared, the liposomes containing the PNAs were lyophilized 
and stored until the usage. Furthermore, LIPO PNA-a210 are stable in serum over the time, as 
shown in Figure 3. FACS measurements were carried out on fluorescent derivatives LIPO-FLUO-
PNA-a210, FLUO-PNA-a210 and FLUO-PNA-a210-R8. The PNA-a210-R8 was used as positive 
control since this PNA is internalized by target cells with very high efficiency, as reported 
elsewhere26. LIPO-FLUO-PNA-a210 is taken up by cells more efficiently than FLUO-PNA-a210, 
which does not enter into cells, and also than FLUO-PNA-a210-R8. This latest result is of particular 
relevance as it suggests that conjugation of PNA to carrier peptides is no longer needed to achieve 
uptake, as far as the correct liposomal formulation is employed. Moreover, the uptake of LIPO-
FLUO-PNA-a210 occurs rapidly, only after 4 hours incubation in K562 cells. As liposomal 
formulations, in particular those possessing anionic and cationic lipids, might be, to some extent 
potentially toxic, we investigated the growth of K562 cells upon incubation with PNA-a210, PNA-
a210-R8, antagomiR-210, empty liposomes, LIPO-PNA-a210 and LIPO-PNA-a210scr. The data 
obtained indicate that the LIPO, LIPO-PNA-a210 and the LIPO-PNA-a210-scr formulation at all the 
concentrations studied did not induce major alterations in cell growth indicating a lack of 
cytotoxicity (Figure S1).  Finally, we investigated the ability of the formulation to down-regulate 
the target miR-210, to verify whether the internalization does not alter biological properties of the 
delivered PNA. LIPO-PNA-a210, unlike PNA-a210, causes a reduction in the expression of miR-210 
at 0.5 M PNA concentration. It is worth highlighting that no toxicity is observed at this 
concentration of liposomal formulation. This result further demonstrates that biological effects 
can be achieved at very low concentrations of PNAs, as far as the delivery is efficient. In addition, 
the extent of the effects of the liposome-delivered PNA resemble that of commercially-available 
antagomiR-210, despite the fact that a comparison is not possible, due to the need of transfection 
reagents to allow antagomiR-210 internalization by target cells. As a final comment, we would like 
to underline that liposome-delivered PNA-a210 maintains its specificity on miR-210 down-
regulation, since the expression of the unrelated miR-221 is not affected by LIPO-PNA-a210 (Figure 
S2). Further efforts are needed to compare liposome-delivered PNAs with R8-delivered PNAs and 
commercially available antagomiRs, including the use of different cell lines, the design of anti-miR 
molecules with different length, PNA sequences targeting different miRNAs, extensive studies on 
miRNA-regulated mRNAs. 
 
Conclusions 
We have reported the first example of a liposomal PNA formulation, in which a PNA oligomer is 
efficiently loaded in a pegylated liposome composition based on the zwitterionic PC phospholipid, 
cholesterol and DSPE-PEG2000. The PNA loaded vehicle is quickly and efficiently delivered inside 
K562 cells, keeping unmodified the biological properties of the delivered PNA. The first important 
implication of this result is that a low concentration of PNA is needed to trigger a biological effect. 
These results will open the way to the use of these oligonucleotide analogues, without further 
modifications, in in vitro and in vivo applications. 
 
Materials and methods 
Protected N-Fmoc-amino acid derivatives, acetic anhydride and coupling reagents have been 
purchased at Novabiochem. Fmoc-PNA-cytosine(Bhoc)-OH, Fmoc-PNA-thymine-OH, Fmoc-PNA-
guanine(Bhoc)-OH, Fmoc-PNA-adenine(Bhoc)-OH were obtained from Link Technologies. 
Acetonitrile (ACN) for LC-MS, N,N-dimethylformamide (DMF) for solid phase synthesis, N, N-
diisopropylethylamine (DIPEA), dichloromethane (DCM) were from Romil Pure Chemistry, 
piperidine from Biosolve. Fmoc-PAL-PEG-PS (0.16 mmol/g) resin was from Applied Biosystems. All 
other chemicals were supplied by Sigma-Aldrich and were used without further purification. 
Egg Phosphatidylcholine (Egg PC; purity, 98%) cholesterol (Chol; purity> 99%) 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[carbonyl-methoxy(polyethylene glycol)2000] (ammonium 
salt) (DSPE-PEG2000) and Rhod-PE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine 
rhodamine B sulfonyl) ammonium salt) were purchased at Avanti Polar Lipids (Alabaster, AL).  
LC-MS analyses were performed on a LC-MS Agilent Technologies 6230 ESI-TOF on a Phenomenex 
Jupiter 3 C18 (150x2.0 mm) column with a flow rate of 0.2 mLmin-1. 
PNA synthesis 
The PNA oligomers were synthesized on a 2mol scale using the standard protocol for the solid 
phase synthesis of PNA39, 40. PNA oligomers were purified by RP-HPLC using a gradient of 
acetonitrile (0.1% TFA) in water (0.1% TFA) from 5 to 50% in 30 minutes and characterized by ESI-
TOF, employing a gradient of acetonitrile (0.05% TFA) in water (0.05% TFA) from 5% to 50% 
applied over 30 minutes.  
PNA antimir210 (PNA-a210) sequence: H-ccgctgtcacacgcacag-NH2. 
mass calculated (Da): 4825.67;  [M+3H]3+: 1609.55  [M+4H]4+: 1207.41; found: [M+3H]3+: 1609.32;  
[M+4H]4+: 1207.24; [M+5H]5+: 965.99. 
PNA antimiR210 scramble (PNA-a210 scr) sequence: H-agcgacgcgatcctcacc-NH2 
mass calculated (Da): 4825.67;  [M+3H]3+: 1609.55  [M+4H]4+: 1207.41; [M+5H]5+: 966.16; found: 
4824.98;        [M+3H]3+: 1609.32;  [M+4H]4+: 1207.24; [M+5H]5+: 965.99. 
PNA antimiR210-R8 (PNA-a210-R8) conjugate synthesis.  
To obtain the PNA-peptide conjugate, we first synthesized the peptide on solid phase following 
standard Fmoc chemistry protocol on a Fmoc-PAL-PEG-PS resin (0.16 mmol/g). The PNA was 
grown on the peptide anchored to the solid phase, following procedures reported above. The 
conjugate was cleaved from the resin and deprotected by treatment with a solution of 78% TFA, 
m-cresol 20%, 2% triisopropylsilane for 3 hours at room temperature. The conjugate was purified 
by RP-HPLC using a gradient of acetonitrile (0.1% TFA) in water (0.1% TFA) from 5 to 50% in 30 
minutes and characterized by ESI-TOF employing a gradient of acetonitrile (0.05% TFA) in water 
(0.05% TFA) from 5% to 50% applied over 30 minutes. 
PNA antimir210-R8 (PNA-a210-R8)  sequence: H-ccgctgtcacacgcacag-RRRRRRRR-NH2. 
mass calculated (Da): 6074.68;  [M+4H]4+: 1519.67; [M+5H]5+: 1215.94; [M+6H]6+: 1013.44; found: 
[M+4H]4+: 1519.25  [M+5H]5+: 1215.60  [M+6H]6+: 1013.16 
 
FLUO-antimiR210 and FLUO-antimiR210-R8 synthesis.  
Derivatization of the PNA and PNA-peptide conjugate with fluorescein was carried out on solid 
phase. To the resins bound oligomers, the fluorescein-5(6)-carboxamidocaproic acid (FLUO-Ahx-
OH) was coupled following standard peptide synthesis protocols for 1 hour, two times. Cleavage 
and deprotection of the conjugates were performed as described earlier. Purification and 
characterization was performed following the protocols described for peptide-PNA conjugates. 
FLUO-PNA antimir210 (FLUO-PNA-a210)  sequence: FLUO-Ahx-ccgctgtcacacgcacag-NH2 
mass calculated (Da):  5327.46; [M+3H]3+:1776.82; [M+4H]4+: 1332.86; [M+5H]5+: 1066.49; found: 
[M+3H]3+: 1766.36; [M+4H]4+: 1325.02;  [M+5H]5+: 1060.42.   
FLUO-PNA antimir210-R8 (FLUO-PNA-a210-R8) sequence: FLUO-Ahx-ccgctgtcacacgcacag-
RRRRRRRR-NH2 
mass calculated (Da): 6576.46; [M+4H]4+: 1645.11; [M+5H]5+: 1316.29; [M+6H]6+: 1097.08; found: 
[M+4H]4+: 1644.99  [M+5H]5+: 1316.19  [M+6H]6+: 1096.99. 
 
Liposome preparation  
 
Three different protocols were tested to obtain PNA loaded liposomes. The same liposomal 
formulation, composed of egg PC/Chol/ DSPE-PEG2000 (47/47/6, molar % ratio) was employed for 
all the protocols. Stock solutions of PNA-antimiR210 and of its fluorescent derivative FLUO-PNA-
antimiR210 were prepared in 10 mM phosphate buffer at pH 7.4, containing the 0.9% wt NaCl and 
100 mM glycerol. Concentrations of all PNA solutions were determined by UV-Vis measurements, 
carried out on Thermo Fisher Scientific Inc (Wilmington, Delaware USA) Nanodrop 2000c 
spectrophotometer equipped with a 1.0 cm quartz cuvette (Hellma) using a molar absorptivity (ε) 
of 172400 M-1 cm-1 at λ = 260 nm. Fluorescent liposomes were prepared by introducing in the 
formulation 0.1% mol/mol of the fluorescent probe Rhod-PE. 
 
a) Thin Film Method/Sonication Method: The required amounts of phospholipids (10.8 mg of PC 
and 5.0 mg of DSPE-PEG2000) and cholesterol (5.4 mg) were dissolved in 3 mL of a 
methanol/chloroform (50/50) mixture; subsequently the organic solvents were removed under a 
stream of nitrogen gas to obtain a homogeneous film on the wall of the vial. Any trace solvent was 
then removed keeping the vial under vacuum for 15 minutes. Then, the dry lipid film was hydrated 
with 3 mL of a solution containing 500μg of PNA- antimiR210 or FLUO-PNA-antimiR210 and 
sonicated in an ultrasound bath for 30 minutes. The liposomal suspension was extruded 10 times 
at room temperature, using a thermobarrel extruder system (Northern Lipids Inc, Vancouver, BC, 
Canada) under nitrogen through a polycarbonate membrane (Nucleopore Track Membrane 25 
mm, Whatman, Brentford, UK) with 0.1 μm pore size. 
b) Freeze/thawing Method: Dry lipid film was prepared as above reported, dissolving 
phospholipids in   a methanol/chloroform (50/50) mixture. Then, the lipid film was hydrated with 
PNAs solutions (500m g of either PNA-a210 and FLUO-PNA-a210 in 3 mL of buffer), and the 
resulting liposomes were frozen/thawed dipping the glass tube for 1 minute into a dry ice bath for 
rapid cooling. The frozen sample was transferred into a bath at 65 °C, allowing it to thaw out for 4 
min, and vortexed for another minute.  Ten cycles were performed to promote the entry of PNAs 
into the liposomes. 
c) SNALPs Method: PNA loaded liposomes were prepared using the spontaneous vesicle formation 
by ethanol dilution method. Lipids (30.0 μmol in 1 mL of ethanol) and PNA (either PNA-a210 and 
FLUO-PNA-a210, 500μg in 3 mL of the buffer) solutions were separately prepared and warmed at 
50°C for 5 minutes. After warming, the lipid solution was rapidly added to the PNA solution and 
then the suspension was extruded 10 times at 50°C with 0.1 μm pore size. 
 
For all methods, the unencapsulated PNA-antimiR210 or FLUO-PNA-antimiR210 were removed 
from the liposomal suspension using a Sephadex G50 gel filtration column, pre-equilibrated with 
10 mM phosphate buffer at pH 7.4, containing the 0.9% wt NaCl and 100 mM glycerol. The 
amount of unloaded PNA eluted from the column was spectroscopically determined by UV-Vis 
measurements at λ = 260 nm. The encapsulation efficiency (EE%, defined as the weight ratio of 
encapsulated PNA versus the amphiphilic molecules forming liposomes) and the encapsulation 
ratio (ER%, defined as the weight percentage of PNA encapsulated in the liposomes on the total 
PNA previously added during preparation) were quantified by subtraction of the amount of 
removed PNA from the total amount of loaded PNA. Liposomes containing PNAs were lyophilized 
and stored at -20°C. The integrity of the reconstituted liposomes was assessed by DLS 
measurements. The leakage of PNA from the liposome was verified loading the reconstituted 
liposomes on a gel-filtration column and measuring the absorbance of the eluates at 260 nm.  
 
DSPE-PEG2000 post-insertion  
    PC/Chol (47/47 molar % ratio) liposomes were prepared and pre-loaded with PNA-a210 or 
FLUO-PNA-a210 by the freeze-thawing method. Liposomes were incubated  with an aqueous 
micellar solution of DSPE-PEG2000 (6% mol) for 2 hours at room temperature under stirring41.  
 
DLS measurements 
Hydrodynamic radii (RH), polydispersity indexes (P.I.) and Z potentials () of filled and empty 
liposomes were measured by Dynamic Light Scattering technique (DLS). DLS measurements were 
carried out using a Zetasizer Nano ZS (Malvern Instruments, Westborough, MA) that employs a 
173° backscatter detector. Other instrumental settings are measurement position (mm): 4.65; 
attenuator: 8; temperature: 25 °C; cell: disposable sizing cuvette. DLS measurements were carried 
out on samples previously prepared, after centrifugation at room temperature at 13,000 rpm for 5 
minutes at 2.010-4 M final lipids concentration. For each formulation, both hydrodynamic radii, 
polydispersity indexes and Z potentials were calculated as the mean of at least three 
measurements on three different batches. 
Serum stability  
  PNA-antimiR210 loaded liposomes (LIPO-PNA-a210) were suspended in 10 mM phosphate buffer 
at pH 7.4 containing 0.9% NaCl at 10 mM lipid concentration and then diluted at 1 mM with fetal 
bovine serum (FBS; Biowest, Nuaillé, France). The colloidal suspension was stirred at 37°C for 72 h. 
Samples withdrawn at different time points (2h, 4h, 8h, 12h, 28, 36h, 48h and 72h) were diluted 
with PBS (1:50 v/v) and analyzed by dynamic light scattering as described earlier.   
PNA uptake by K562 cells 
To determine the PNA uptake, flow cytometry analyses (BD FACScan) were performed. In order to 
observe uptake kinetics, K562 cells were seeded at initial concentrations of 3 x 105 per well in 24-
well plates for 4, 24 and 48 hours. Cells were grown at 37˚C in 5% CO2
 in fresh culture medium 
RPMI 1640 (Lonza BioWhittaker, Basel, Switzerland) supplemented with 10% FBS and incubated 
with PNA-a210, PNA-a210-R8 or LIPO-PNA-a210 at final concentrations of 2µM and 4µM. After the 
treatment, cells were centrifuged at 1800 rpm for 5 minutes, washed in PBS (Lonza BioWhittaker, 
Basel, Switzerland) with 1% FBS and suspended in 200µl PBS with 1% FBS.  For each sample, 30000 
events were analysed and fluorescence emission at 515-545 nm (FL1) was detected, using BD Cell 
Quest Pro. The intracellular distribution of FLUO-LIPO-PNA-a210 was first studied by microscopy 
analysis of living cells using the BioStation instrument, a compact cell incubation and monitoring 
system (BioStation IM, Nikon Instruments Europe B.V., Italy), previously demonstrated to be a 
suitable system to detect intracellular distribution of fluorescein-labelled PNAs25, 42. Then, the cells 
were fixed, counterstained with 4,6-diamidino-2- phenylindole (DAPI) 25 for nuclear labelling and 
further analysed. Live images of cells treated with FLUO-PNA-a210 and Rho-LIPO-FLUO-PNA-a210 
were also obtained using a Nikon Swept Field Confocal equipped with CFI Plan Apo VC60XH 
objective (numerical aperture, 1.4) (Nikon Instruments, Melville, NY, USA) and an Andor DU885 
electron multiplying charge- coupled device (EM-CCD) camera (Andor Technology Ltd, Belfast, 
Northern Ireland). Acquired images were then analyzed by using open source software Fiji 43, 44. 
 
 
Transfection protocols for standard RNA   antagomiR 
 
The transfection of the anti-microRNAs was carried out following the protocol reported by  
Ambion (Applied Biosystems, Foster City, CA, USA) and described elsewhere27. 30000 K562 cell/ml 
were seeded in 24-well plates. Treatments with increasing concentrations of antagomiR-210 (AM-
105116 Applied Biosystems, Foster City, CA, USA) were performed using the siPort NeoFX 
transfection reagent.   
Quantitative analyses of miRNAs 
Reverse transcriptase (RT) reactions were performed using the TaqMan® MicroRNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA, USA); real-time PCR was performed 
according to the manufacturer’s protocols. 500 ng of total RNA per sample were used for the 
assays. All RT reactions, including no-template controls and RT-minus controls, were performed in 
duplicate using the CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad Laboratories, Milan, 
Italy). The relative expression was calculated using the comparative cycle threshold method and 
as reference U6 snRNA was used to normalize all RNA samples, since it remains constant in the 
assayed samples by miR-profiling and quantitative RT-PCR analysis, as previously reported45. 
 
Statistical analysis 
All the data were normally distributed and presented as mean ± S.D. Statistical differences 
between groups were compared using one-way ANOVA (ANalyses Of VAriance between groups) 
software. Statistical differences were considered significant when p< 0.05 (*), highly significant 
when p< 0.01 (**). 
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